Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07486830 · ClinicalTrials.gov registry record · Phase 2
IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction
A Phase 2 study of Provoked Vestibulodynia, sponsored by Center for Vulvovaginal Disorders.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 2
- Study locations
NCT07486830: Recruiting Phase 2 study of Provoked Vestibulodynia, sponsored by Center for Vulvovaginal Disorders.
NCT07486830 is a Phase 2 study of Provoked Vestibulodynia that is actively recruiting participants, run by Center for Vulvovaginal Disorders. The registered enrollment target is 54 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07486830, a Phase 2 study of Provoked Vestibulodynia, is actively recruiting participants, sponsored by Center for Vulvovaginal Disorders.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a double-blind, placebo-controlled study evaluating the safety and efficacy of incobotulinumtoxinA (Merz) for the treatment of provoked vestibulodynia (PVD) associated with overactive pelvic floor muscle dysfunction. Eligible participants are premenopausal females aged 18 years and older with a confirmed diagnosis of PVD with hypertonic pelvic floor muscles, established by both an expert physician and an expert pelvic floor physical therapist. Participants must have bilateral provoked pain at the posterior vestibule on cotton swab testing and a pain score of 5 or greater on an 11-point Numeric Rating Scale (NRS) during standardized dilator testing at baseline. Key outcome measures include change in pain during dilator testing and Patient Global Impression of Change (PGI-C). Participants with anterior vestibular pain, prior botulinum toxin injection in the genitopelvic area within the past 12 months, or significant genitourinary conditions that may confound assessment are excluded.
Primary Outcome
maximum dilator size tolerated
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Incobotulinum Toxin A
Study Locations (2)
District of Columbia
- Center for VulvoVaginal Disorders - Washington D.C.
New York
- Centers for Vulvovaginal Disorders, NY - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2026-02-27 |
| Est. Completion | 2027-03-03 |
| Phase | Phase 2 |
What NCT07486830 shows while recruiting
NCT07486830 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Provoked Vestibulodynia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07486830 reports a single indexed study location in District of Columbia, New York.
Frequently Asked Questions
What is clinical trial NCT07486830 about?
NCT07486830 is a clinical study titled "IncobotulinumtoxinA for Provoked Vestibulodynia With Overactive Pelvic Floor Muscle Dysfunction". This is a double-blind, placebo-controlled study evaluating the safety and efficacy of incobotulinumtoxinA (Merz) for the treatment of provoked vestibulodynia (PVD) associated with overactive pelvic floor muscle dysfunction. Eligible participants are premenopausal females aged 18 years and older wit...
What is the current status of trial NCT07486830?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2026-02-27. Estimated completion is 2027-03-03.
What conditions does trial NCT07486830 study?
This clinical trial studies the following conditions: Provoked Vestibulodynia.
What interventions are being tested in trial NCT07486830?
The interventions under investigation include: Placebo (DRUG), Incobotulinum Toxin A (DRUG).
Who is sponsoring clinical trial NCT07486830?
This trial is sponsored by Center for Vulvovaginal Disorders, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07486830 being conducted?
This trial has 2 study locations across District of Columbia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Provoked Vestibulodynia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07486830's enrollment target sits among peer trials
54 1160th of 2000 higher than 831 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI